As of September 18, 2026, Eli Lilly and Company (LLY) trades at $1153.60. Equity Rank's blended estimate across 10 valuation models with sufficient data is $670.13 — a model fair value differential of 41.9% below the current price under these model assumptions. Model-derived estimate, informational only — not investment advice.
Eli Lilly and Company (LLY) is next scheduled to report earnings on Oct 29, 2026 (before market open). The consensus analyst EPS estimate for the upcoming quarter is $9.56.
Heading into this report, the model's fair value estimate sits 41.9% below the current price (model fair value differential below current price). Descriptive context only — not a forecast of the earnings result.
Equity Rank computed model fair value for LLY from 10 independent valuation methods with sufficient data. 1 place fair value above the current price of $1153.60, and 9 place it below. The model-blended estimate lands at $670.13 — a model fair value differential of 41.9% below the current price under these model assumptions. The larger group places fair value below the current price.
Equity Rank's fundamental strength composite scores LLY at 78.3/100 (A-, Strong), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at +24.9% per year and gross margin has moved +6.3 pp. Its SAVE composite score has moved -0.7 over the past 30 days.
Equity Rank's intrinsic value estimate for Eli Lilly and Company (LLY) — the model fair value — is $670.13 as of September 18, 2026, blended from 10 valuation methods with sufficient data. An intrinsic value estimate is what the models compute a share to be worth under stated assumptions; it is not a price target, not a prediction of where the stock will trade, and not investment advice.
Equity Rank calculates fair value for LLY by blending 19 valuation methods (8–15 run per security depending on data availability), including DCF, Graham Number, Price-to-Free-Cash-Flow, EPV, Three-Stage DCF, DDM, Residual Income, and Justified Price-to-Book. Each model is weighted by historical sector accuracy and updated regularly. Informational only — not investment advice.
Eli Lilly and Company (LLY) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Eli Lilly and Company (LLY) is classified in the Drug Manufacturer sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
Side-by-side valuation: LLY vs PFE · LLY vs MRK
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks